Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Revolutionary Bio: Plans to acquire 42% equity of Yujing Pharmaceutical for approximately 4.05 million yuan
Revolutionary Biological Announcement: The company plans to acquire 42% of the equity interest in Yujing Pharmaceutical Co., Ltd. (Beijing) held by the existing shareholders Lin Changqing, Chen Jianguo, Wang Fan, and He Zhili, for RMB 4.05 million. Upon completion of this acquisition, the company will hold 100% of the equity interest in Yujing Pharmaceutical Co., Ltd. (Beijing). This related-party transaction has been considered and approved by the company’s independent directors’ special meeting; all members unanimously agreed to the matter and agreed to submit it to the company’s board of directors for deliberation. This related-party transaction has also been approved at the 10th meeting of the company’s fourth session of the board of directors; related party director Lin Changqing recused himself from voting, and non-related party directors unanimously agreed. As this related-party transaction falls within the approval authority of the board of directors, it does not need to be submitted to the company’s shareholders’ meeting for approval.